Le Lézard
Classified in: Health, Science and technology
Subject: TRI

"Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery"

SHENZHEN, China, Sept. 25, 2023 /PRNewswire/ -- On September 15, "Kexing Biopharm 2023 Innovation Forum on Targeted Drug Delivery" successfully kicked off. This marks the first time in recent years that the Company has organized an event specifically focused on pharmaceutical R&D innovation.

The forum focused on LNP- and extracellular vesicle-based drug delivery systems covering topics such as development trend, clinical research, process development, novel system design, and ideas on innovation. Prominent industry experts and academic scholars were invited to deliver great speeches, including Prof. Liu Bicheng, dean of the School of Medicine of Southeast University, Prof. Wang Yucai, professor of the University of Science and Technology of China and founder of Hefei RNAlfa Biotechnology Co., Ltd., and Dr. Xu Ke, founder and CEO of VesiCURE Therapeutics Co., Ltd.

Guided by platform-based corporate strategy "Innovation + Internationalization", Kexing Biopharm has formulated R&D plans emphasizing "Molecule Generation", "NMPA/FDA dual IND Filing" and "Out-licensing". The goal is to develop innovative medicines that address unmet medical needs, and build cutting-edge technology platforms. Supported by its well-established technologies for creating novel protein and antibody-based biologics, the Company's pipeline features programs in the areas of cancer, autoimmune and degenerative diseases. Meanwhile, Kexing Biopharm is setting up an exosome-based drug delivery platform, progressing to the next level of scientific innovation and laying a foundation for its nucleic acid therapeutics technology platform.

In 2021, Kexing Biopharm partnered with Southeast University to establish the "Innovation Laboratory for Commercial Production of Extracellular Vesicle-based Drug Delivery Technology". This laboratory focuses on the application and clinical transformation of hucMSC- and HEK293-derived exosomes in the field of nephropathy. Moreover, research on large-scale exosome production and quality control was carried out to establish a novel and efficient drug loading and delivery system. This endeavour aims to offer a Chinese solution for more precise disease treatment, in the hope of benefiting patients with new technologies at an earlier date.


These press releases may also interest you

at 16:05
NetApptm , a global, cloud-led, data-centric software company, today announced the Company will participate in firesides chat at the following conferences: UBS TMT Conference Phil Brotherton, VP, Solutions & Alliances December 5, 2023 Presentation:...

at 16:05
Lattice Semiconductor Corporation , the low power programmable leader, today announced that its Board of Directors authorized the Company to repurchase up to an additional $250 million of its outstanding common stock through the end of December 2024....

at 16:05
Porch Group, Inc. ("Porch", "Porch Group" or "the Company") , a leading vertical software company reinventing the home services and insurance industries, today releases its initial Environmental, Social and Governance ("ESG") report. This report...

at 16:05
POSaBIT Systems Corporation (the "Company" or "POSaBIT"), a leading provider of payments infrastructure in the cannabis industry, today announced its financial results for the three and nine months ended September 30, 2023. "Since our inception,...

at 16:01
CleanSpark, Inc. (the "Company"), America's Bitcoin Minertm, today reported financial results for its fiscal year ended September 30, 2023....

at 16:00
Adweek, the leading source of news, insights and intelligence for the marketing and advertising industry, today announced it has hired Zoë Ruderman, former Vice President and General Manager of People, as Chief Content Officer and Drew Schutte,...

News published on and distributed by: